VivoSeq
Other

Hypercholesterolaemia

4

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Hypercholesterolaemia is an early-stage landscape with 4 programs across 5 companies. The most active players are Novartis, AstraZeneca, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

88/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

4 programs

Phase 2AstraZeneca logo

AstraZeneca

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalA

Amryt Pharma

0 programs

PreclinicalM

Moon (Guangzhou) Biotechnology Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 24

QCZ484

Novartis

Inclisiran

Novartis

QCZ484 Placebo

Novartis

Inclisiran Placebo

Novartis

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
RNA therapy150%

Modality classified for 50% of 4 pipeline programs.

Analysis

Trial Status

12

clinical trials

Completed7 · 58%
Recruiting2 · 17%
Unknown status1 · 8%
Terminated1 · 8%
Active, not recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Preliminary Efficacy of Akkermansia Muciniphila AKM Lab-01 in Subjects With Hypercholesterlemia
Recruiting·MMoon (Guangzhou) Biotechnology Co., Ltd.·Preclinical·NCT06974266·60 enrolled
A Multicenter, Randomized, Double-blind, Factorial Design Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of HDY015 Administered as a Free Combination of QCZ484 and Inclisiran Compared to QCZ484, Inclisiran, and Placebo in Participants With Hypertension and Concomitant Hypercholesterolemia
Recruiting·Novartis logoNovartis·Phase 2·NCT07610278·120 enrolled
Specified Drug-use Survey of Leqvio for s.c. Injection (Familial Hypercholesterolaemia or Hypercholesterolaemia, CKJX839A11401)
Active, not recruiting·Novartis logoNovartis·N/A·NCT06275724·585 enrolled
Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS)
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT00654225·2,340 enrolled
Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT00653744·1,700 enrolled
A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing Medication
Completed·Sanofi logoSanofi·Phase 4·NCT00655265·86 enrolled
Alirocumab and Plaque Burden In Familial Hypercholesterolaemia
Completed·FFundación Hipercolesterolemia Familiar·Phase 4·NCT05465278·104 enrolled
An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT01078675·315 enrolled
Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)
Completed·AAmryt Pharma·Phase 3·NCT04681170·46 enrolled
Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP)
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT00653965·3,000 enrolled
Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg
Terminated·AstraZeneca logoAstraZeneca·Phase 4·NCT00427960·55 enrolled
Postprandial Lipid Metabolism in Familial Hypercholesterolaemia:Effects of Fish Oils
Unknown status·TThe University of Western Australia·N/A·NCT01577056·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)